key: cord-0806764-bygb670d
authors: Hashimoto, Takanao; Ozaki, Akihiko; Bhandari, Divya; Sawano, Toyoaki; Murayama, Anju; Shrestha, Sunil; Sah, Ranjit; Tanimoto, Tetsuya; Montenegro-Idrogo, Juan J.; Rodriguez-Morales, Alfonso J.
title: Limited capacity of SARS-CoV-2 variants testing in Japan: A secondary analysis using publicly available data
date: 2021-07-21
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2021.102145
sha: 05df77047882f77b28d529095a646a311008d439
doc_id: 806764
cord_uid: bygb670d

nan

As of early 2021, the widespread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the emergence of more virulent genetic variants globally, which is more infectious with a high mortality rate [1, 2] . Hence, a rapid elucidation of the details of SARS-CoV-2 genetic variants, their infectious capacity, and regional surveys to assess the incidence are crucial to controlling the spread of the virus. In Japan, a country early affected in the pandemic [3, 4] , a variant of concern 202012/01 was first identified in the airport quarantine station on December 25, 2020. Concerned about the further spread of SARS-CoV-2, the Japanese government declared a second state of emergency from January 8 to March 21, 2021.

Under these circumstances, it is imperative to establish a system for variant testing and identify the actual spread of infection accurately. The Japanese government temporarily set a goal of increasing the variant testing ratio for RT-PCR-positive cases to 40 % to strengthen the variant surveillance system. Consequently, the various mass media have also reported anecdotal trends in variant testing, especially the ups and downs of variant testing ratio. However, this has not been rigorously evaluated in academic literature. Furthermore, it has not been verified whether the variant testing ratios were arranged based on the actual spread of infection or whether Japan's policy in variant testing was appropriate. Therefore, to summarize the trend of variant testing ratios against the number of positive RT-PCR cases and the number of variant positive cases in Japan, we conducted a secondary analysis of publicly available but piecemeal data, firstly published by several governmental agencies scattered way (https://www.mhlw.go.jp).

We retrieved and examined open data on RT-PCR testing and N501Y variant tests in Japan both on a national and prefectural basis (htt ps://www.mhlw.go.jp). The 47 prefectures of Japan were categorized according to the population densities; the three most populated prefectures (the capital city Tokyo, Osaka, and Kanagawa) were shown individually, and the remaining 44 prefectures were divided into quartiles equally. We investigated the information on the number of RT-PCR cases, positive cases, RT-PCR positive ratio, variant cases, and the variant test ratios (the number of variant tests divided by the number of SARS-CoV-2 positive cases) on the whole country from February 22 to April 11, 2021. For the data per prefecture, only the variant test ratios were shown due to data availability.

In Japan as a whole, the proportion of RT-PCR positive cases among the total number of RT-PCR tests increased from 2.3 % (February 22 to 28, 2021) to 5.6 % (April 5 to 118, 2021) ( Table 1 ). The variant test ratios among total RT-PCR positive cases were consistently less than 40 % throughout the study period, although they were upward from 17.4 % (February 22 to 288, 2021) to 36.3 % (April 5 to 118, 2021) (Table 1) . Additionally, the proportions of variant positive cases among total variant tests steadily increased from 4.5% (56/1234) to 46.0% (3489/ 7581) during the study period. Concerning comparing the RT-PCR test positive cases receiving the variant testing in each region by the population densities, high-density prefectures had fewer proportions than in the low-density prefectures throughout the entire study period (Table 1 ).

This study found that the variant test ratio among RT-PCR positive cases increased to just below 40 % in early April 2021. That means that the Japanese government has almost achieved its original goal set for variant testing. However, a worrying fact is that both the proportions of RT-PCR positive cases per RT-PCR testing and variant-positive cases per variant testing have been continuously rising. As such, the Japanese government was forced to declare a state of emergency on April 25, 2021, for the third time (https://www.mhlw.go.jp). That poses a question for variant testing strategy by the Japanese government so far and needs further scrutiny for improvement.

We also compared the results by prefectures and found that the proportions of RT-PCR-positive cases who underwent the variant test were lower in prefectures with higher population densities than those with lower population densities throughout the entire period. The primary reason might be the limited capacity of variant testing in densely populated prefectures.

Under the current testing system in Japan, a certain number of [5] . According to recent data from the genomic surveillance reported to the GISAID platform (https://nextstrain.org/ncov/), the variants of concern alpha and delta are currently present in Japan, in addition to the clades 19A, 20C, and 20B (Fig. 1) . In this context, genomic surveillance would be crucial for estimating the virulence to spread infection and predict the disease's severity [6] . Also, a prefecture-wise analysis will help us understand the actual geographical and temporal distribution of the concern variants. By doing so, we can analyze their actual impact and learn about their transmission routes, infectivity, morbidity and mortality. In conclusion, to cope with the rapidly expanding and diversifying variants, we call for establishing a more sophisticated variant testing system, including genome analysis, as soon as possible in Japan (Fig. 1) .

TH wrote the first draft of the manuscript. All authors critically revised the manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work, and approved the final manuscript.

None.

Dr Ozaki reports personal fees from Medical Network Systems, MNES Inc., outside the submitted work. Dr Tanimoto reports personal fees from Medical Network Systems, MNES Inc. and Bionics co. Ltd., outside the submitted work. Dr. Rodriguez-Morales, report being medical advisor of Abbott Diagnostics for Latin America, outside the submitted work. All the other authors report no conflicts of interest.

COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic

Variants, vaccines and vaccination passports: challenges and chances for travel medicine in 2021

The COVID-19 outbreak and implications for the Tokyo 2020 summer olympic games

Limiting spread of COVID-19 from cruise ships: lessons to be learnt from Japan

Tokyo bureau of social Welfare and public health

Genomic surveillance for SARS-CoV-2 variants